Vicore Pharma Holding AB (publ) (VICO)
Free
No email, no account, no signup.
Pulling latest news for Vicore Pharma Holding AB (publ)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Signal
HOLD
Sentiment
7/10
Risk
7/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Order analysis – $4.99
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment has improved modestly on ASPIRE being fully recruited and the board’s commercial strengthening, but the market remains centered on binary risk into the 2027 topline readout and ongoing burn rate.
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Drug development in fibrotic lung diseases
Market Cap
$257M
Market sentiment
Sentiment has improved modestly on ASPIRE being fully recruited and the board’s commercial strengthening, but the market remains centered on binary risk into the 2027 topline readout and ongoing burn rate.
Why HOLD ?
Maintain HOLD: ASPIRE full recruitment reduces near-term execution risk and funding remains solid, but the key value driver is still binary (ASPIRE topline) with a long time to readout.
- Keep the current position; consider adding only on clear data-driven signals (e.g., strong ATS/biomarker support) or on a larger dip without fundamental deterioration. Alternatively, scale exposure closer to the 2027 readout if risk budget allows.
Recent News
- Since 2026-04-06: (1) Phase 2b ASPIRE (buloxibutid in IPF) has completed recruitment (last patient in). (2) Q1 2026 report released May 6: continued losses but cash/short-term investments still just above SEK 1.0bn as of Mar 31, 2026 and operating cash flow around -SEK 118m. (3) AGM on May 6 approved authorization to issue up to 20% new shares and new incentive programs. (4) Peter Guenter elected to the Board on May 7. (5) ATS May 15–20 posters/presentations including AIR Phase 2a analyses and translational AT2R mechanism work.
Bull case
- **Strong cash balance** after the directed raise reduces near-term funding pressure.
- **ASPIRE enrollment** nearing completion can support positive news flow.
Unlock to read more →
Bear case
- **High burn rate** can weigh on sentiment without new data.
Unlock to read more →
Catalysts
15 May 2026 — ATS 2026: AIR data and translational posters
Dilution Risk
Assessment: Medium
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Vicore Pharma Holding AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.